Takeda Pharmaceutical (TAK) Long-Term Debt Repayments (2020 - 2026)

Takeda Pharmaceutical's Long-Term Debt Repayments history runs 7 years deep, the most recent figure standing at -$478.4 million for Q1 2026.

• On a quarterly basis, Long-Term Debt Repayments rose 86.41% year-over-year to -$478.4 million in Q1 2026; TTM through Mar 2026 was -$1.3 billion, a 84.54% increase from a year earlier, with the FY2026 full-year figure at -$1.3 billion, up 84.65% from the prior year.
• Long-Term Debt Repayments retreated to -$478.4 million in Q1 2026 per TAK's latest filing, from -$149451.7 in the prior quarter.
• Across five years, Long-Term Debt Repayments topped out at -$149451.7 in Q4 2025 and bottomed at -$3.5 billion in Q1 2025.
• The 5-year median for Long-Term Debt Repayments is -$567.6 million (2023), against an average of -$963.3 million.
• Biggest YoY gain for Long-Term Debt Repayments was 100.0% in 2025; the steepest drop was 620894.46% in 2025.
• Year by year, Long-Term Debt Repayments stood at -$1.8 billion in 2022, then jumped by 71.96% to -$505.5 million in 2023, then plunged by 550.65% to -$3.3 billion in 2024, then jumped by 100.0% to -$149451.7 in 2025, then slumped by 319999.56% to -$478.4 million in 2026.
• Per Business Quant, the three latest TAK Long-Term Debt Repayments figures stand at -$478.4 million (Q1 2026), -$149451.7 (Q4 2025), and -$604021.6 (Q3 2025).